Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Micron Technology, Inc. (MU) Price & Performance

Mesoblast LimitedTrade
Micron Technology, Inc.Trade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Micron Technology, Inc. — how do they compare? Mesoblast Limited trades at $16.86 (market cap $2.21B), while Micron Technology, Inc. trades at $930.05 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 443.8× Mesoblast Limited's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESOMU
Market Cap
$2.21B$980.90B
Sector
TechnologyTechnology
52-Week High
$20.96$1.21K
52-Week Low
$12.88$115.79
Enterprise Value
$2.21B$961.25B
Dividend Yield
0.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Micron Technology, Inc.

Micron Technology (MU) trades at $925.24, up 7.46% with strong earnings momentum after beating Q1 2026 EPS estimates of $20.98 with $25.11. The stock shows bearish technical signals despite robust fundamentals including 55.91% net margin and 32.62% ROE. Recent news highlights AI-driven memory demand growth but concerns about cyclicality and competitive threats from new entrants like SpaceX's Terrafab facility.

Outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target, though technical weakness and memory market cyclicality pose near-term risks. The company's strategic customer agreements provide revenue visibility through 2030, supporting long-term growth potential despite current bearish technical indicators.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Micron Technology, Inc.

Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.

Read more on MU